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Recombinant human alpha-N-acetylglucosaminidase-insulin-like growth factor-2 (rhNAGLU-
IGF2) is an investigational enzyme replacement therapy for Sanfilippo B, a lysosomal storage 
disease. Because recombinant human NAGLU (rhNAGLU) is poorly mannose 6-
phosphorylated, we generated a fusion protein of NAGLU with IGF2 to permit its binding to the 
cation-independent mannose 6-phosphate receptor. We previously administered rhNAGLU-IGF2 
intracerebroventricularly to Sanfilippo B mice, and demonstrated therapeutic restoration of 
NAGLU, normalization of lysosomal storage, and improvement in markers of neurodegeneration 
and inflammation. Here, we studied intracerebroventricular rhNAGLU-IGF2 delivery in both 
murine and canine Sanfilippo B to determine potential effects on their behavioral phenotypes and 
survival. Treated mice showed improvement in disease markers such as heparan sulfate 
glycosaminoglycans, beta-hexosaminidase, microglial activation, and lysosomal-associated 
membrane protein-1.  Sanfilippo B mice treated with rhNAGLU-IGF2 displayed partial 
normalization of their stretch attend postures, a defined fear pose in mice (p<0.001). We found a 
more normal dark/light activity pattern in Sanfilippo B mice treated with rhNAGLU-IGF2 
compared to vehicle-treated Sanfilippo B mice (p=0.025). We also found a 61% increase in 
survival in Sanfilippo B mice treated with rhNAGLU-IGF2 (mean 53w, median 48w) compared 
to vehicle-treated Sanfilippo B mice (mean 33w, median 37w; p<0.001). In canine Sanfilippo B, 
we found that rhNAGLU-IGF2 administered into cerebrospinal fluid normalized HS and beta-
hexosaminidase activity in gray and white matter brain regions. Proteomic analysis of cerebral 
cortex showed restoration of protein expression levels in pathways relevant to cognitive function, 
synapse, and the lysosome. These data suggest that treatment with rhNAGLU-IGF2 may 
improve the phenotype of Sanfilippo B disease. 
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Lysosomal storage diseases are a heterogenous group of inherited disorders characterized 
by accumulation of undegraded substrate within lysosomes. Typically, these disorders are caused 
by an inability to perform an enzymatic reaction, often due to deficiency in the production or 
function of a lysosomal hydrolase. Sanfilippo (types A-D) is together one of the most common 
lysosomal storage diseases, with incidence estimates ranging from 1 in 25,000 to 100,000.1,2 
Approximately fifteen percent of Sanfilippo disease is type B. 1 The lysosomal storage material 
in Sanfilippo syndromes is the glycosaminoglycan heparan sulfate. The disease is associated 
with progressive neurodegeneration, typically with onset in early childhood.2 In the clinic, 
soluble lysosomal hydrolases are available in recombinant form for some types of lysosomal 
storage disease, and may be delivered by repeated infusion into the bloodstream or into the 
cerebrospinal fluid.3–9 However, no therapeutic options are currently approved for Sanfilippo 
syndrome. 
To function as a therapeutic enzyme, a recombinant lysosomal hydrolase requires 
appropriate post-translational modification including glycosylation with mannose 6-phosphate 
(M6P).10 Mannose 6-phosphate residues bind to mannose 6-phosphate receptors (M6PRs) 
expressed on the endosomal-lysosomal membrane, and results in transport of the enzyme from 
the Golgi apparatus to the lysosome, where it is active and catabolizes substrate in the acidic 
environment of this organelle. One of the lysosomal hydrolases, the enzyme alpha-N-acetyl-
glucosaminidase (NAGLU) that is responsible for Sanfilippo B syndrome (or 
mucopolysaccharidosis type IIIB, MPS IIIB), is not properly processed when produced 
recombinantly.11,12 A fusion protein that contains the therapeutic enzyme (recombinant human 
NAGLU; rhNAGLU) plus a peptide fragment of IGF2, which can bind the cation-independent 
M6PR, forming rhNAGLU-IGF2 demonstrated improved intracellular uptake and reduction of 
lysosomal storage in Sanfilippo B fibroblasts.13 Using a mouse model, intracerebroventricular 
(ICV) delivery of rhNAGLU-IGF2 demonstrated therapeutic restoration of NAGLU, 
normalization of lysosomal storage, and dramatic improvement in markers of neurodegeneration 
and inflammation.14 Neonatally administration of rhNAGLU-IGF2 showed a treatment effect 
that lasted more than four weeks after a single ICV dose.15 A commercial form of rhNAGLU-
IGF2 has reached clinical trials.16–18 
Recombinant enzymes delivered into cerebrospinal fluid can penetrate into deep brain 
structures and improve neuropathology in preclinical studies,19–22 and there is one recombinant 
therapeutic enzyme approved for intracerebroventricular administration in patients for the late-
infantile form of neuronal ceroid lipofuscinosis (CLN2 disease).8 Here, we studied the effect of 
intracerebroventricular rhNAGLU-IGF2 on behavior and survival in Sanfilippo B mice and 
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Mouse model: Naglu-/- mice (B6.129S6-Naglutm1Efn/J, backbred onto the C57BL6/J strain for at 
least 10 generations) were produced by crossing -/- male mice with +/- female mice, thus 
generating approximately 50% affected progeny. Mice received research grade recombinant 
human NAGLU-IGF2 (100 µg), NAGLU (100 µg), or an equivalent volume (~5 µl) of vehicle 
(artificial cerebrospinal fluid (CSF)) in the left lateral ventricle beginning at PND 2 by manual 
injection.  At four weeks of age, mice were cannulated into the left ventricle, and the infusion of 
enzyme/vehicle was given via cannulae at 28-day intervals until 16 weeks of age. To prevent 
possible allergic reactions, mice received premedication with diphenhydramine 5 mg/kg 
intraperitoneally 15 min prior to infusions.  Research grade NAGLU-IGF2, NAGLU, and vehicle 
were provided by BioMarin Pharmaceutical, Inc. (Novato, CA). Experimental personnel were 
blinded as to treatment of either therapeutic enzymes or vehicle (coded “1, 2 or 3”). All animal 
experiments were approved by the institutional animal use committees at the Los Angeles 
Biomedical Research Institute at Harbor-UCLA Medical Center (now the Lundquist Institute) in 
Torrance, CA, and Washington University School of Medicine in St. Louis, MO.  
Behavior: Male Sanfilippo B “mutant” mice and male carrier” mice were used for the behavior 
assessment at the UCLA Behavior Core. Mice of both sexes were used for studies at Washington 
University School of Medicine in St. Louis. Elevated plus maze, novel object recognition, and 
social interaction tests were performed at the UCLA Behavioral Testing Core as previously 
described.23 The final infusion dose was given at 16 weeks of age, then infusion cannulae were 
removed before behavioral testing at 16-20 weeks of age was performed. Mice in these 
experiments were male and the implantation of cannulae prevented them from being caged with 
other males. To prevent confounding of behavioral experiments due to social isolation, these 
males were cohoused with a female companion and permitted to breed.  This cohort of mice 
were sacrificed at 20 weeks old following behavioral assessments.  
To test motor coordination (vestibular and cerebellar function), cohorts of mice of both sexes 
were studied at Washington University School of Medicine in St. Louis, Missouri. Animals were 
tested on rotarod (UGO Basile, Verese, Italy) at 32 and 40 weeks as described.24 Briefly, a 
rocking paradigm with reversal of direction of rotation after each full turn at 10 rpm for 3 
minutes was executed for 3 consecutive days at 32 and 40 weeks of age. For each time point, 
training was provided for 2 consecutive days with 3 trials each day and 20 minutes of rest 
between each trial. Testing occurred on the third consecutive day and the length of time each 
mouse remained on the rod was recorded for all three trials and averaged. Activity in an open 
field was assessed over 24 h in a rectangular polystyrene enclosure surrounded by photobeams 
monitored by computer software (MotorMonitor, Kinder Scientific, Poway, CA).25 Testing 
consisted first of a 12 h block with the room lights off (“dark”) and ended with a 12 h block with 
the room lights on (“light”). Mice had access to food and water ad libitum during testing. 
Outcome measures included number of rearing events, distance traveled, and time spent resting. 
The mice were sacrificed at 40 weeks old following behavioral assessments.  
Survival: In the survival experiment mutant mice were given monthly infusion starting at PND2 
with vehicle (8 males, 8 females) or rhNAGLU-IGF2 (8 males, 8 females) as well as carrier mice 
given vehicle (3 males, 13 females) or rhNAGLU-IGF2 (8 males, 8 females). The survival 
experiment was carried to humane endpoints and terminated with the death of the last treated 
mutant mice.  
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Biochemical assays: NAGLU activity and total hexosaminidase activity were quantified using 
4-methylumbelliferyl assays as previously described.14 Briefly the enzymatic activity of NAGLU 
and NAGLU–IGF2 was determined by hydrolysis of the fluorogenic substrate, 4-
methylumbelliferyl-N-acetyl-α-glucosaminide, obtained from CalBiochem (now EMD Millipore 
Chemicals) or Toronto Research Chemicals, with minor modifications of a published protocol, 
using 1.0 mM substrate in the incubation mixture.26 Enzymatic activity of beta-hexosaminidase 
(combined A and B isoforms) was determined by hydrolysis of 4-methylumbelliferyl-N-acetyl-β-
glucosaminide (EMD Millipore Chemicals, Darmstadt, Germany) using 1.25 mM substrate in the 
incubation mixture. For both enzymes, a unit of activity is defined as release of 1 nmol of 4-
methylumbelliferone (4MU) per hour. Protein concentration was estimated by the Bradford 
method, using bovine serum albumin as a standard. 
Analysis of heparan sulfate was performed by BioMarin Pharmaceutical (mouse tissues) or the 
UC San Diego GlycoAnalytics Core (canine tissues) as described previously.27 Tissues were 
homogenized and digested overnight with Pronase (Sigma-Aldrich, St. Louis, MO) in phosphate-
buffered at 37 °C and centrifuged at 14,000 rpm for 20 min. The supernatant was passed through 
a DEAE column, and the bound GAG was eluted with 2 M NaCl. The GAG was then desalted on 
PD10-size exclusion column, and purified GAG was lyophilized. Dried GAG disaccharides were 
dissolved in aniline and reacted with freshly prepared sodium cyanoborohydride solution in a 
dimethyl sulfoxide/acetic acid mixture (7:3, v/v). Reactions were carried out at 65 °C for 1 h 
followed by 37 °C for 16 h. The samples were then dried using a speed vacuum at room 
temperature. Aniline-tagged disaccharides were separated on a C18 column using an ion pairing 
solvent mixture and analyzed by mass spectrometry in negative ion mode. 
Immunostaining: Mice were anesthetized with isoflurane and perfused transcardially with 
heparinized PBS followed by 4% paraformaldehyde in neutral PBS. After post-fixation in this 
solution for an additional 48 hours, the brains were removed and cryoprotected in 30% sucrose in 
50 mM tris buffered saline, pH=7.6. A one in six series of 40 µm coronal brain sections from 
each mouse were stained on slides using a modified immunofluorescence protocol for the 
following antibodies: rat anti mouse CD68, 1:400 (Bio Rad, Hercules, CA, cat # MCA1957), 
rabbit anti-LAMP1, 1:400  (Abcam, Cambridge, MA, cat# Ab24170). The intensity of 
immunostaining was assessed using a semi-automated thresholding image analysis method, as 
described previously, using Image Pro-Premier software (MediaCybernetics, Chicago, IL).28  
Canine model: Canine experiments were conducted at Iowa State University under protocols 
approved by the institutional animal care and use committee. Sanfilippo B dogs were produced 
by breeding homozygous affected males to carrier females. Affected dogs were anesthetized and 
a 22-gauge needle inserted into the cisterna magna. CSF (0.2 to 0.5 ml) was collected free-
flowing. A syringe was attached to the needle hub to deliver rhNAGLU-IGF2 (diluted to 3 ml in 
sterile saline) over 2-3 minutes. Dogs in the treatment group received rhNAGLU-IGF2 at 1 week 
of age and again at 4 weeks of age and were euthanized at 8 weeks of age (4 weeks after the 
second dose). Dose was calculated per estimated brain weight. At one week of age, canine brains 
are roughly 1/38 of body weight, and the administered dose was 400 mg rhNAGLU-IGF2/kg 
brain, or approximately 7 mg. For a 2.5 kg four week-old pup, in which brain weight is 1/60 of 
body weight, the dose was approximately 17 mg.  Control group animals were not treated. At 
necropsy, terminal CSF and blood were collected, and dogs were perfused with chilled PBS and 
brains removed. Brains were sliced coronally into 4 mm slabs using a pre-chilled, stainless steel 
canine brain matrix (ASI Instruments) as described elsewhere.29 A 3 mm skin punch was used to 
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collect samples from cerebral gray matter, cerebral white matter, caudate, and cerebellar vermis. 
Samples were snap-frozen in an isopentane bath on dry ice. 
Proteomics Snap-frozen canine samples (approximately 1x1x0.4 cm) from a parasagittal gyrus, 
including gray matter and subcortical white matter were analyzed by LC/MS/MS at Caltech. 
Protein lysates from canine brain cortex samples were prepared using Thermo EasyPrep Mini 
MS Sample Prep Kit (cat# A4006). Protein concentrations were determined using Bradford (Bio-
Rad) and 100 μg total protein from each sample were prepared for mass spectrometry acquisition 
using Thermo EasyPep Mini MS Sample Prep Kit. After determining peptide concentrations by 
Pierce Quantitative Fluorometric Peptide Assay (cat# 23290), 20 μg peptide from each sample 
was labeled with TMT10plex Isobaric Label Reagent Set (ThermoFisher Scientific, cat# 
A37725) following to the manufacture's instruction. Labeled samples were combined and dried 
using vacuum centrifugation. Samples were then separated into 8 fractions using the High pH 
reversed-phase peptide Fractionation Kit (ThermoFisher Scientific, cat# 84868). The fractions 
were dissolved with 0.1% formic acid and peptide concentration was determined with 
Quantitative Colorimetric Peptide Assay (ThermoFisher Scientific, cat# 23275). 
TMT labeling LC-MS/MS experiments were performed using an EASY-nLC 1000 connected to 
an Orbitrap Eclipse Tribrid mass spectrometer (Thermo Scientific). 0.5 μg of each fraction was 
loaded onto an Aurora AUR2-25075C18A UHPLC Column  (IonOpticks, Fitzroy, Australia) and 
separated over 131 min at a flow rate of 0.4 μL/min with the following gradient: 2-6% Solvent B 
(2 min), 6-22% B (78 min), 22-50% B (40 min), 50-95% B (1 min), and 95% B (10 min). 
Solvent A consisted of 97.8% H2O, 2% ACN, and 0.2% formic acid, and solvent B consisted of 
19.8% H2O, 80% ACN, and 0.2% formic acid. An MS1 scan was acquired in the Orbitrap at 
120k resolution with a scan range of 400-1600 m/z. The AGC target was 1 × 106, and the 
maximum injection time was 50 ms. Dynamic exclusion was set to exclude features after 1 time 
for 60 s with a 10-ppm mass tolerance. MS2 scans were acquired with CID activation type with 
the IonTrap. The isolation window was 0.7 m/z, the collision energy was 35%, the maximum 
injection time was 35 ms and the AGC target was 1 x 104. MS3 scans were acquired with HCD 
activation type in the Orbitrap at 60k resolution with a scan range of 100-500 m/z. The isolation 
window was 0.7 m/z, the collision energy was 65%, the maximum injection time was 118 ms 
and the AGC target was 2.5 x 105. Ion source settings were as follows: ion source type, NSI; 
spray voltage, 2300 V; ion transfer tube temperature, 300°C. System control and data collection 
were performed by Xcalibur software (ThermoFisher Scientific). 
Data analysis: Graphs were produced on GraphPad Prism (version 9 or 9.1; GraphPad Software, 
San Diego, CA) or SigmaPlot version 14.0 (Systat Software Inc., San Jose, CA). Linear 
regression was performed using SigmaPlot. Statistical analysis of continuous variables was 
performed on Stata (version 16) using ANOVA. The proteomic data processing was performed 
through Proteome Discoverer 2.4 (ThermoFisher Scientific) using Uniprot canine database and 
the SequestHT with Percolator validation.30,31 Normalization was performed relative to the total 
peptide amount. Further analyses were performed as below: limma analyses were performed 
using R studio following the user guide;32 volcano plot was generated with Origin 2019b; DE 
proteins were tested for enrichment analysis using g:Profiler33 and plotted with Prism 7 
(GraphPad Software, San Diego, CA); heatmaps were generated with Prism 7. 
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Lysosomal storage: Male and female mice received ICV injections of rhNAGLU-IGF2, 
rhNAGLU, or vehicle at PND2. They were cannulated at 4 weeks of age and received 
therapeutic enzyme or vehicle via cannulae at monthly intervals until 16 weeks of age and 
sacrificed 4 weeks later. Brain and heart showed a reduction in HS that reached statistical 
significance for each treatment group compared to vehicle-treated MUT mice (p<0.001, Fig. 1). 
All intergroup differences were statistically significant by ANOVA. There was some residual 
NAGLU enzymatic activity detected in mouse brains in both treatment groups despite the 28-day 
interval from the final dose and tissue collection (Supplemental Table S1). We found 
improvement in disease-associated markers such as beta-hexosaminidase (Supplemental Table 
S2), CD68 (Fig. 2), and LAMP1 (Fig. 3) in mice treated with rhNAGLU or rhNAGLU-IGF2.  
 
Fig. 1. Heparan sulfate (HS) concentrations in the (A) brain and (B) heart of experimental mice 
and controls. MUT: Sanfilippo B (Naglu-/-) mice. CAR: heterozygous carrier (Naglu +/-) mice 
that are expected to be phenotypically unaffected. VEH: vehicle. NAG-IGF2: recombinant 
human NAGLU-IGF2, NAGLU: recombinant human NAGLU. Treatments and vehicle were 
administered intracerebroventricularly as described in the methods. Units are expressed in mg of 
wet weight, with means and standard deviation shown. N=8 per group, p<0.001 MUT VEH vs. 
MUT NAGLU or MUT NAG-IGF2.  
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Fig. 2. CD68 Immunoreactivity. (A-L) Immunofluorescence staining with anti-CD68 (green) in 
the primary somatosensory cortex (S1BF) and striatum (caudate and putamen) in mice. Red 
boxes indicate insets for the panels below. Scalebar 100 µm in panels A-D and I-L. Scalebar 500 
µm in panels E-H. (M-N) Bar graphs depict means and standard deviations of thresholding 
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image analysis. N=4-9 per group. *p<0.01. MUT: Sanfilippo B (Naglu-/-) mice. CAR: 
heterozygous carrier (Naglu +/-) mice that are expected to be phenotypically unaffected. VEH: 
vehicle. NAGLU: recombinant human NAGLU.  NAG-IGF2: recombinant human NAGLU-
IGF2.   
 
Fig. 3. LAMP1 Immunoreactivity. (A-H) Immunofluorescence staining with anti-LAMP1 (red) 
in the primary somatosensory cortex (S1BF) and striatum (caudate and putamen) in mice. 
Scalebar 100 µm. (I-J) Bar graphs depict means and standard deviations of thresholding image 
analysis. N=4-9 per group. **p<0.001. MUT: Sanfilippo B (Naglu-/-) mice. CAR: heterozygous 
carrier (Naglu +/-) mice that are expected to be phenotypically unaffected. VEH: vehicle. 
NAGLU: recombinant human NAGLU.  NAG-IGF2: recombinant human NAGLU-IGF2.   
 
Behavior: Male Sanfilippo B and control mice were treated with rhNAGLU, rhNAGLU-IGF2, 
or vehicle from PND2 to 16 weeks as described in the methods. We previously found that 
Sanfilippo B mice show reduced measures associated with fear in mice, as evidenced by 
decreased stretch attend postures on the elevated plus maze.23 This difference between WT and 
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mutant mice was again seen here (Fig. 4), with a more normal number of stretch attend postures 
in mice treated with either rhNAGLU or rhNAGLU-IGF2.  
 
Fig. 4. Count of stretch attend postures (SAP) during testing on the elevated plus maze. Carrier 
(“CAR”) mice are Naglu+/-, mutant (“MUT”) are Naglu-/-. Carrier and mutant mice were treated 
with vehicle (“VEH”). VEH: vehicle. NAGLU: recombinant human NAGLU.  NAG-IGF2: 
recombinant human NAGLU-IGF2.  Carrier mice treated with rhNAGLU or rhNAGLU-IGF2 
did not differ from carrier mice treated with vehicle (not shown). Each dot = one mouse, with 
means and s.e.m. shown. N=7-14 per group. 
 
We did not find significant intergroup differences between vehicle-treated Sanfilippo B mice and 
controls in radial arm maze performance, social interaction testing, or novel object recognition 
testing (Supplemental Figures S1-S4). 
Survival: Sanfilippo B and control mice were treated with rhNAGLU-IGF2 or vehicle (four 
groups; Fig. 5). The experiment was terminated after the last mutant mouse died. Results 
indicate a 58% increase in survival in Sanfilippo B mice treated with rhNAGLU-IGF2 (mean 
52w, median 48w) compared to vehicle-treated Sanfilippo B mice (mean 33w, median 37w; 
p<0.001). Causes of death and other adverse events (mainly loss of cannulae and reimplantation) 
are described in Supplemental Table S3.  
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Fig. 5. Survival curves for Sanfilippo B mice (Mut) and carrier controls (Car) treated with ICV 
vehicle (Veh) or rhNAGLU-IGF2 (NAG-IGF2) monthly from PND 2. N=16 per group, males 
and females. P<0.001 Mut-Veh v Mut-NAG-IGF2. 
 
Dark/light activity: Patients with Sanfilippo B show abnormal circadian rhythm, including poor 
or inverted sleep patterns.34 Sanfilippo B mice and controls were treated from PND 2 with 
monthly rhNAGLU-IGF2 or vehicle (four groups). At age 22 weeks, Sanfilippo B mice showed 
greater activity during the dark phase than heterozygous control mice, reaching statistical 
significance for number of rears (Fig. 6). A more normal sleep/activity pattern was seen in 
Sanfilippo B mice treated with rhNAGLU-IGF2. Total time resting was similar across groups, 
but vehicle-treated Sanfilippo B mice covered more total distance than treated mutant mice or 
carrier controls, although this difference did not reach statistical significance.  
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Fig. 6. Activity in dark and light phases of open field by genotype and treatment group. (A) 
Overall distance traveled. (B) Number of rears. (C) Time spent resting. Mutant + vehicle, n=3. 
Mutant + NAG-IGF2, n=9. Carrier + vehicle, n=7. Carrier + NAG-IGF2, n=3. 
 
Motor Coordination: This experiment involves Sanfilippo B mice and controls treated from 
PND 2 with monthly rhNAGLU-IGF2 or vehicle (4 groups). Rotarod testing at 32 and 40 weeks 
are shown in Fig. 7. Sanfilippo B mice treated with vehicle showed slightly reduced rotarod 
performance at 32 weeks (p<0.001), with further worsening at 40 weeks (p<0.001). Sanfilippo B 
mice treated with rhNAGLU-IGF2 showed no reduction in rotarod performance at 32 weeks, but 
showed a decrease in performance at 40 weeks compared to vehicle-treated or rhNAGLU-IGF2-
treated carrier mice, but remained significantly better than vehicle-treated mutant mice (all 
p<0.001). One Sanfilippo B mouse treated with vehicle died between weeks 32 and 40.  
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Fig. 7 Time to fall off rotarod in Carrier (+/-) and Mut (-/-) Sanfilippo B mice treated with 
vehicle or NAGLU-IGF2 (NAG-IGF2) ICV monthly from PND 2. Mice were studied at 32 and 
40 weeks. Mut – Vehicle, n=3 at 32 weeks and n=2 at 40 weeks; Mut – NAG-IGF2, n=9; Carrier 
+ vehicle, n=20; Carrier + NAG-IGF2, n=3. p<0.001 for MUT-Vehicle v MUT-NAG-IGF2 at 
both timepoints. 
 
Canine studies: In this experiment, three Sanfilippo B dogs received two doses of rhNAGLU-
IGF2, approximately 7 mg at 1 week and approximately 17 mg at 4 weeks of age, into the 
cerebrospinal fluid at the cisterna magna and were sacrificed at 8 weeks of age, four weeks 
following the second and final dose. Three untreated Sanfilippo B dogs and three untreated 
carrier dogs were used as controls. Sanfilippo B dogs showed increased HS and beta-
hexosaminidase levels in most brain regions compared to controls (Fig. 8). These disease-
associated changes were reduced essentially to normal levels in treated animals, even in deeper 
regions of brain such as white matter and caudate nucleus. Some NAGLU activity was detected 
in brain tissue despite a four-week interval from the date of the final rhNAGLU-IGF2 dose and 
tissue collection (Supplemental Table S4).  
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Fig. 8 Canine Sanfilippo B. Sanfilippo B dogs (MUT) and carrier controls (CAR) were treated 
with intra-cisternal rhNAGLU-IGF2 (NAG-IGF2) or untreated at 1 and 4 weeks of age and 
sacrificed at 8 weeks (n=3 per group, both sexes). (A) Box plot of heparan sulfate (HS) in left 
cerebral gray matter (CGM). MUT v CAR and MUT NAG-IGF2 v MUT were statistically 
significant at p<0.01. (B) Regression curve showing HS in cerebrospinal fluid (CSF) versus HS 
in CGM.  (C) Box plot of heparan sulfate (HS) in CSF. Open circles represent individual 
animals. MUT v CAR and MUT NAG-IGF2 v MUT were statistically significant at p<0.01. (D) 
Beta-hexosaminidase in brain regions (means and standard deviation). CSO: centrum semiovale. 
CN: caudate nucleus. CGM: cerebral gray matter. CWM: cerebral white matter. *p<0.05 MUT 
NAG-IGF2 v MUT.  
 
Proteomic analysis was performed on cerebral cortical samples of each animal at the Chou lab as 
described in the Methods (Fig. 9). Tandem mass tag (TMT) 10-plexed labelling was employed to 
evaluate the proteomic changes in Sanfilippo B mutant animals. Specifically, we prepared three 
independent biological wild type (CAR), Sanfilippo B (MUT) and rhNAGLU-IGF2-treated 
Sanfilippo B (ERT) canine brain cortex samples. The TMT labeled samples were pooled and 
further fractionated into 8 fractions and analyzed with the RTS-SPS-MS3 method.35 A total of 
5806 proteins were identified, and 4442 of these proteins were quantified across all 9 samples 
(Supplemental Table S5). We identified 309 proteins that demonstrated significantly di erent 
quantities (p < 0.05) between the untreated Sanfilippo B (MUT) and wild type (CAR) samples 
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(Supplemental Table S6) by limma analysis. Among them, a set of 41 proteins with log2 (fold 
change) >0.5 (up-regulated) or <-0.5 (down-regulated) was classified as the final di erentially 
expressed proteins (DEPs) (Fig. 9A, Supplemental Table S7). Subsequently, functional 
enrichment analysis was performed on these 41 DEPs. The top four relevant changed cellular 
components in the significantly enriched GO terms and top four changed KEGG or REAC 
functional pathways are presented in Fig. 9B. The GO: CC analysis showed these DEPs were 
mainly located at lysosome, secretory granule, extracellular matrix, and in vesicles. Pathway 
analysis indicated the DEPs primarily related to Glycosaminoglycan degradation, Keratan sulfate 
degradation, Neutrophil degranulation, and Innate Immune System. As shown in Fig. 9C, ERT 
therapy reversed several proteins that were down-regulated in mutant animals compared to 
carrier controls, such as DPP7 and CALB2. Notably, most of the elevated protein expression 
seen in Sanfilippo B canines were reversed by ERT, including GNS, LAMP1, HEXB, and CD63,
among others. These results provide valuable insights for identifying novel hallmarks of 




Fig. 9 Proteomic analysis in canine Sanfilippo B. Experimental animals were the same as in Fig. 
8 and included heterozygous carriers (CAR), Sanfilippo B (MUT), and rhNAGLU-IGF2-treated 
Sanfilippo B (ERT) groups. Proteins were analyzed from canine brain cortex. (A) Volcano plot 
displaying the proteomic changes in Sanfilippo B mutant, n=3. (B) Functional enrichment 
analysis of the differently expressed proteins affected by Sanfilippo B mutant. (C) Heatmap 
displaying the scaled abundance of the differently expressed proteins affected by Sanfilippo B 
mutant and rhNAGLU-IGF2 treatment.  
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Previously, we studied the biochemical and pathological efficacy of ICV rhNAGLU-
IGF2 against biochemical and pathological outcome measures in Sanfilippo B mice. Here, we 
extended this analysis to assess its effectiveness on behavior and survival. Our behavioral 
assessments were designed to separately evaluate the behaviors that might be impacted by 
physical disease, such as motor activity and balance, from behaviors that are primarily 
representative of altrered neocortical function, such as fear behavior. We found evidence that 
rhNAGLU-IGF2 administration improved survival, physical disease, and fear behavior in 
Sanfilippo B mice. Some but not all of these studies also included an experimental group that 
received rhNAGLU (without IGF2), and we found an equivalent improvement in the outcomes 
we evaluated in the rhNAGLU-treated mice as the rhNAGLU-IGF2-treated mice. 
Our study had a number of important limitations. First, the rhNAGLU-IGF2 that was 
available for our studies was not materially the same as the clinical candidate that is currently in 
clinical trials. We do not know the differences in composition between the clinical candidate 
material and the research grade enzyme that we used here. Second, our studies were not designed 
to evaluate the biodistribution of either rhNAGLU or rhNAGLU-IGF2 in the central nervous 
system. This is because our chosen study termination occurred four weeks after the final dose, 
following behavioral studies. The half-life of rhNAGLU-IGF2 in the brain was previously 
estimated at approximately seven days,14 although mice treated at postnatal day 1 or 2 showed 
elevated NAGLU activity at four weeks following a single ICV injection of rhNAGLU-IGF2.15 
However, the dose of enzyme (100 µg) was not increased as the mice grew15, so that in this study 
little to no enzyme could be detected in the brain of these mice at four weeks after the final 
infusion. This limitation also meant that we were unable to determine the cellular distribution of 
the enzymes within tissues. Third, some behavioral assessments such as radial arm maze and 
social interaction test did not show intergroup differences between carriers and affected mice 
during this experiment, so that we could not use these tests to determine whether there was a 
therapeutic effect in treated cohorts. All the mice were cannulated, which may have affected their 
behavior and clearly limited the types of experiments we could conduct; for example, we were 
not able to perform Morris water maze testing in cannulated mice. Both control and treatment 
group experimental mice also underwent repeated sedation in order to dose vehicle or enzyme, 
and it was important to keep treatment as consistent as possible among groups. However, the 
repeated sedation events may have affected behavioral experiments and impacted overall 
survival, even in the otherwise healthy carrier mice. 
Our results raise the question of the importance of M6PR-mediated uptake in effective 
enzyme replacement therapy for the brain. Studies in vitro using human fibroblasts revealed that 
efficient uptake of lysosomal enzymes into this cell type is nearly completely dependent on 
M6PRs. Similarly, neuronal cell lines appear to also rely on M6PRs for intracellular uptake, 
suggesting that treating these disease-critical cells requires the use of this system.15,36,37 
Conversely, in vitro and in vivo studies of Sanfilippo B and other lysosomal disorders have 
demonstrated that macrophage-lineage cells do not depend entirely on M6PRs to engulf material 
from the extracellular milieu,38,39 and this has also been observed for mouse microglial cells 
incubated with rhNAGLU.36 A limited study by the Neufeld laboratory found that rhNAGLU 
administered intravenously to Sanfilippo B mice localized to tissue macrophages.40 Notably, 
macrophage targeting was sufficient to nearly normalize HS levels in systemic tissues that were 
accessible to circulating enzyme from the bloodstream. This raises two possibilities: either 
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macrophage-targeting is sufficient to treat Sanfilippo B disease, or perhaps more likely, whole-
tissue measurements of HS do not sufficiently measure therapeutic response.   
Microglia are macrophage-lineage cells of the central nervous system, and expected 
therefore to take up even enzymes that lack mannose 6-phosphate residues or their equivalent to 
some extent. There is ample evidence of microgliosis in Sanfilippo B disease,29,41,42 but the role 
of microglial activation and other inflammatory cascades in this disorder is not clear. One 
possibility in explaining our findings is that the behavioral and neuropathological outcomes that 
are frequently used to evaluate Sanfilippo B mice may only reflect the inflammatory components 
of the disease. Treatment of Sanfilippo B mice with the immunosuppressive steroid prednisolone 
improved rotarod performance and survival, suggesting a contributory role of inflammation in 
the manifestations of disease in the mouse model.43 An unanswered question, therefore, is 
whether this “inflammatory component” is the primary disease driver of neurological impairment 
in Sanfilippo B disease in the mouse model, and more importantly, in humans.  
Alternatively, another possible explanation for our findings is that the chosen dose and 
frequency did not reveal differences between the efficacy of rhNAGLU and rhNAGLU-IGF2 
that might otherwise have been apparent. We observed that neither rhNAGLU nor rhNAGLU-
IGF2 completely treated Sanfilippo B disease in this experiment. It is possible that a different 
dose or frequency of rhNAGLU-IGF2 administration, would have provided a more robust 
therapeutic effect compared to rhNAGLU. If the dose and frequency were too high, nonspecific 
enzyme uptake would be expected to occur and possibly eliminate the predicted differences 
between the native and fusion protein forms of enzyme. Alternatively, if the dose were too low, 
microglial and perivascular cell uptake could have been predominant in both the rhNAGLU and 
rhNAGLU-IGF2-treated groups. In this scenario, both rhNAGLU and rhNAGLU-IGF2 would 
have treated mainly these glial cells and not sufficiently treated the neurons directly, resulting in 
a phenotypic improvement corresponding to correction in inflammatory and other supportive 
cells only. Even with enzymes that are well mannose 6-phosphorylated, such as recombinant 
human alpha-L-iduronidase (for Hurler syndrome also known as MPS I) for example, 
distribution studies of intravenously administered enzyme showed preferential localization in 
sinusoidal cells with lesser staining appearing in hepatocytes. There could be a “threshold effect” 
at work, in which saturating macrophage-lineage cells is necessary prior to sufficient uptake into 
the target cells. It is not clear whether rhNAGLU or rhNAGLU-IGF2 were taken up into neurons 
in vivo in the brain during the experiments described here, because we were not able to assess 
biodistribution in our studies for the reasons described above. Previously published studies of 
rhNAGLU-IGF2 did show staining for NAGLU in neurons,14 but the dosing interval for that 
study was higher – four doses in two weeks – compared to the monthly dosing described here. If 
monthly dose and frequency of administration of rhNAGLU-IGF2 was inadequate to treat 
neurons yet sufficient to induce behavioral improvements, this implies that our phenotypic read-
outs in Sanfilippo B mice are not sufficient to measure the neurological disease process and the 
impact of treatment upon this.  
Besides enzyme replacement therapy, another approach in development is gene therapy 
to deliver the coding sequence for NAGLU as a theoretically permanent means of correction. 
Studies of adeno-associated viral vectors used to deliver NAGLU to Sanfilippo B mice show 
improvements in HS, neuropathology, behavior, and survival that are similar to those reported 
here for recombinant enzyme administration.44,45 However, it is not known whether cells that are 
transduced by viral vectors bearing the NAGLU transgene produce NAGLU that is properly 
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mannose 6-phosphorylated. Nevertheless, in vitro studies of NAGLU secreted by cells 
transduced using adeno-associated viral vector-2 demonstrated that the secreted NAGLU was 
able to correct intracellular HS accumulation as evidenced by an 35SO4 assay.
46 These authors 
did not study competitive inhibition of this effect by mannose 6-phosphate43, so it is not clear 
whether the enzyme used that receptor system for uptake. It has long been understood for 
mucopolysaccharidosis that the concentration of enzyme that is required for correction of 
glycosaminoglycan accumulation is far lower than that required to demonstrate intracellular 
uptake of active enzyme.47 In this respect, both rhNAGLU-IGF2 and rhNAGLU were capable of 
reducing intracellular HS in human Sanfilippo B fibroblasts in vitro, although 10-fold higher 
concentrations of rhNAGLU compared to rhNAGLU-IGF2 were required to achieve this effect.36 
To study mannose 6-phosphorylation of NAGLU in the context of gene therapy, induced 
pluripotent stem cells derived from Sanfilippo B mouse embryonic fibroblasts were transduced 
with lentivirus bearing the human NAGLU transgene under a cytomegalovirus promoter.48 The 
supernatant from these cells was added to Sanfilippo B patient fibroblasts in the presence or 
absence of mannose 6-phosphate. The study demonstrated uptake of NAGLU from the 
supernatant of these lentiviral-modified cells into Sanfilippo B fibroblasts that was nearly 
completely abolished with the addition of mannose 6-phosphate to the media, suggesting that 
NAGLU produced by gene therapy may not suffer the same post-translational processing issues 
as recombinant NAGLU enzyme produced by cells in vitro, as was used in this study.    
The importance of treating systemic disease due to Sanfilippo B syndrome is also not 
known. Cardiac involvement is described in patients, including valvular heart disease, 
myocardial thickening, and arrhythmia.49,50 The disease course is progressive, and while 
currently cardiac involvement is not a driver of mortality or even major symptoms due to 
Sanfilippo B syndrome, it seems probable that if neurological disease is successfully treated any 
morbidity from heart disease would become more evident. CSF bulk turnover occurs multiple 
times per day (approximately three times per day in humans), and so it is expected that 
recombinant enzymes administered into the cerebrospinal fluid would reach the blood circulatory 
system, albeit at a lower concentration, from which they would be taken up by organs and tissues 
outside the central nervous system. It is not known whether this approach of delivering enzymes 
to the cerebrospinal fluid in order to treat both the central nervous system and the rest of the 
body would be sufficient, holistic therapy for Sanfilippo disease. 
Canine proteomic analysis revealed altered expression of lysosomal proteins, such as 
elevation of alpha-N-acetylglucosamine-6-sulfatase (GNS), cathepsin D (CTSD), and beta-
hexosaminidase (HEXB). These results are not surprising, as lysosomal enzymes and other 
proteins may show elevated activity levels in tissues of Sanfilippo B mice compared to controls. 
Marked deficiency in the protein dipeptidyl peptidase 7 (DPP7), has not to our knowledge been 
previously associated with Sanfilippo B syndrome. Dipeptidyl peptidase 7 is a serine protease 
that localizes to non-lysosomal vesicles and shows substrate specificity similar to that of the cell-
surface protein dipeptidyl peptidase 4.51 Interestingly, HS and heparin oligosaccharides may 
inhibit the activity of dipeptidyl peptidase 4.52 Low expression of collagen type I alpha1 
(COL1A1), collagen type I alpha2 (COL1A2), and fibulin 5 (FBLN5), proteins implicated in 
connective tissue disorders, was found in Sanfilippo B dogs compared to controls, with more 
normal expression in treated animals. Deficiency in collagen and fibulin is not known to be 
associated with Sanfilippo B syndrome, although these proteins and HS-containing 
proteoglycans are components of the extracellular matrix.   
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Long-term treatment with monthly intracerebroventricular rhNAGLU-IGF2 (research grade) 
showed a beneficial effect in Sanfilippo B mice. Significant intergroup differences were noted in 
survival, motor activity, stretch attend postures (fear behavior), and histological markers of 
microglial activation, and lysosomal substrate accumulation (beta-hexosaminidase, LAMP1) 
between enzyme-treated and vehicle-treated Sanfilippo B mice. Whole tissue brain and heart HS 
levels were lower in Sanfilippo B mice treated with rhNAGLU compared to rhNAGLU-IGF2. 
We did not detect other intergroup differences between rhNAGLU and rhNAGLU-IGF2-treated 
mice in the outcome measures that we assessed in these experiments. Notably, our studies were 
not designed to assess NAGLU distribution, and only one experiment included treatment groups 
with both enzymes. Sanfilippo B dogs treated with rhNAGLU-IGF2 showed less HS in brain and 
CSF compared to untreated affected controls, with beta-hexosaminidase activity normalized to 
carrier levels in most cerebral areas including gray and white matter regions. Proteomics studies 
in cerebral cortex showed dysregulated pathways in Sanfilippo B dogs compared to carrier 
controls, with restoration of a more normal pattern in Sanfilippo B dogs treated with rhNAGLU-
IGF2. These findings suggest that rhNAGLU-IGF2 administered into cerebrospinal fluid shows a 
beneficial effect on the Sanfilippo B phenotype in multiple species. 
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